CVMP Assessment Report for Innovax-ND-IBD to Add a New Route

CVMP Assessment Report for Innovax-ND-IBD to Add a New Route

21 March 2019 EMA/193705/2019 Veterinary Medicines Division Committee for Medicinal Products for Veterinary Use CVMP assessment report for Innovax-ND-IBD to add a new route of administration (in ovo) for chicken embryonated eggs (EMEA/V/C/004422/X/0001) Vaccine common name: Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant) Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction ................................................................................................ 4 Marketing authorisation under exceptional circumstances ................................................ 4 Scientific advice .......................................................................................................... 4 MUMS/limited market status ........................................................................................ 4 Part 1 - Administrative particulars .............................................................. 4 Detailed description of the pharmacovigilance system ..................................................... 4 Manufacturing authorisations and inspection status ......................................................... 5 Overall conclusions on administrative particulars ............................................................ 5 Part 2 – Quality ........................................................................................... 5 Chemical, pharmaceutical and biological/microbiological information (quality) .................... 5 Qualitative and quantitative particulars of the constituents............................................... 5 Qualitative and quantitative particulars .......................................................................... 5 Containers and closures ............................................................................................... 6 Product development ................................................................................................... 6 Description of the manufacturing method....................................................................... 6 Production and control of starting materials ................................................................... 7 Starting materials listed in pharmacopoeias ................................................................... 7 Specific materials not listed in a pharmacopoeia ............................................................. 7 Starting materials of biological origin ............................................................................. 7 Starting materials of non-biological origin ...................................................................... 8 In-house preparation of media and solutions consisting of several components .................. 8 Control tests during the manufacturing process .............................................................. 8 Control tests on the finished product ............................................................................. 8 Batch-to-batch consistency .......................................................................................... 9 Stability ..................................................................................................................... 9 Overall conclusions on quality ..................................................................................... 10 Part 3 – Safety .......................................................................................... 10 Introduction and general requirements ........................................................................ 10 Safety documentation ............................................................................................... 11 Laboratory tests ....................................................................................................... 12 Safety of the administration of one dose ...................................................................... 12 Safety of one administration of an overdose ................................................................. 12 Safety of the repeated administration of one dose ........................................................ 13 Examination of reproductive performance .................................................................... 13 Examination of immunological functions ...................................................................... 13 Special requirements for live vaccines ......................................................................... 14 Spread of the vaccine strain ....................................................................................... 14 Dissemination in the vaccinated animal ....................................................................... 15 Reversion to virulence of attenuated vaccines .............................................................. 15 Biological properties of the vaccine strain..................................................................... 15 Recombination or genomic re-assortment of the strains ................................................. 15 CVMP assessment report for Innovax-ND-IBD to add a new route of administration (in ovo) for chicken embryonated eggs (EMEA/V/C/004422/X/0001) EMA/193705/2019 Page 2/40 User safety .............................................................................................................. 16 MRLs ....................................................................................................................... 16 Withdrawal period ..................................................................................................... 16 Interactions ............................................................................................................. 16 Field studies ............................................................................................................. 17 Environmental risk assessment ................................................................................... 19 Considerations for the environmental risk assessment ................................................... 19 Environmental risk assessment for products containing or consisting of genetically modified organisms ................................................................................................................ 19 Overall conclusions on the safety documentation .......................................................... 20 Part 4 – Efficacy ........................................................................................ 21 Introduction and general requirements ........................................................................ 21 Challenge model: ...................................................................................................... 21 Efficacy parameters and tests: ................................................................................... 21 Efficacy documentation .............................................................................................. 21 Laboratory trials ....................................................................................................... 23 Dose determination ................................................................................................... 23 Onset of immunity .................................................................................................... 23 Duration of immunity ................................................................................................ 29 Maternally derived antibodies (MDA) ........................................................................... 31 Interactions ............................................................................................................. 32 Field trials ................................................................................................................ 36 Overall conclusion on efficacy ..................................................................................... 37 Part 5 – Benefit-risk assessment ............................................................... 38 Introduction ............................................................................................................. 38 Benefit assessment ................................................................................................... 39 Direct therapeutic benefit .......................................................................................... 39 Additional benefits .................................................................................................... 39 Risk assessment ....................................................................................................... 39 Risk management or mitigation measures .................................................................... 40 Evaluation of the benefit-risk balance .......................................................................... 40 Conclusion ............................................................................................................... 40 CVMP assessment report for Innovax-ND-IBD to add a new route of administration (in

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    40 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us